Abstract:Objective: This review aimed to assess the current use and acceptance of real-world data (RWD) and real-world evidence (RWE) in health technology assessment (HTA) process. It additionally aimed to discern stakeholders’ viewpoints concerning RWD and RWE in HTA and illuminate the obstacles, difficulties, prospects, and consequences associated with the incorporation of RWD and RWE into the realm of HTA. Methods: A comprehensive PRISMA-based systematic review was performed in July 2022 in PubMed/Medline, Scopus, IDEAS-RePEc, International HTA database, and Centre for Reviews and Dissemination with ad hoc supplementary search in Google Scholar and international organization websites. The review included pre-determined inclusion criteria while the selection of eligible studies, the data extraction process and quality assessment were carried out using standardized and transparent methods. Results: Twenty-nine ( n = 29) studies were included in the review out of 2,115 studies identified by the search strategy. In various global contexts, disparities in RWD utilization were evident, with randomized controlled trials (RCTs) serving as the primary evidence source. RWD and RWE played pivotal roles, surpassing relative effectiveness assessments (REAs) and significantly influencing decision-making and cost-effectiveness analyses. Identified challenges impeding RWD integration into HTA encompassed limited local data access, complexities in non-randomized trial design, data quality, privacy, and fragmentation. Addressing these is imperative for optimal RWD utilization. Incorporating RWD/RWE in HTA yields multifaceted advantages, enhancing understanding of treatment efficacy, resource utilization, and cost analysis, particularly via patient registries. RWE complements assessments of advanced therapy medicinal products (ATMPs) and rare diseases. Local data utilization strengthens HTA, bridging gaps when RCT data is lacking. RWD aids medical device decision-making, cancer drug reassessment, and indirect treatment comparisons. Challenges include data availability, stakeholder acceptance, expertise, and privacy. However, standardization, training, collaboration, and guidance can surmount these barriers, fostering enhanced RWD utilization in HTA. Conclusion: This study highlights the intricate global landscape of RWD and RWE acceptance in HTA. Recognizing regional nuances, addressing methodological challenges, and promoting collaboration are pivotal, among others, for leveraging RWD and RWE effectively in healthcare decision-making.

[Methodology progress and challenges on assessing the appropriateness of real-world data]

Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union

Preliminary Assessment of the Data Appropriateness of Electronic Health Records for Real-World Studies: A Survey of Hospitals in a Developing Region in China

Assessing The Practice Of Data Quality Evaluation In A National Clinical Data Research Network Through A Systematic Scoping Review In The Era Of Real-World Data

Advancing the development of real-world data for healthcare research in China: challenges and opportunities

Real-World Data for Healthcare Research in China: Call for Actions.

Existing barriers and recommendations of real-world data standardisation for clinical research in China: a qualitative study

Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process

Methodological Challenges using Routine Clinical Care Data for Real-World Evidence: a Rapid Review utilizing a systematic literature search and focus group discussion

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Utilization of real-world evidence in clinical research of medical devices

The Use of Real‐World Evidence for Regulatory Decisions in China

The use of real-world data for clinical investigation of effectiveness in drug development

[Progress in methodological research on bridging the efficacy-effectiveness gap of clinical interventions (1): to improve the validity of real-world evidence]

The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

A Review of Data Quality Assessment Methods for Public Health Information Systems

Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory Submission

Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings.

Enriching Real-world Data with Social Determinants of Health for Health Outcomes and Health Equity: Successes, Challenges, and Opportunities

Real-world data: a brief review of the methods, applications, challenges and opportunities